Novozymes B Receives Positive Analyst Updates
Novozymes B, a Danish company specializing in industrial enzymes and microorganisms, has received positive updates from several analysts. The company’s stock price has likely been influenced by these developments.
Danske Bank and Berenberg have both increased their price targets for Novozymes B to 570 and 530 Danish kronor, respectively. These revised targets represent a significant increase from previous estimates.
The analysts have also reaffirmed their “buy” recommendations for Novozymes B. This suggests that the company is well-positioned for growth and may be a promising investment opportunity.
Key Updates:
- Danske Bank increased its price target to 570 Danish kronor
- Berenberg increased its price target to 530 Danish kronor
- Both analysts reaffirmed their “buy” recommendations for Novozymes B